 - Indication for long-term Vitamin-K antagonist VKA therapy based on the presence of previous ischemic stroke, transient ischemic attack TIA or systemic embolism andor at least two of the following risk factors: hypertension requiring drug treatment, moderately or severely impaired left ventricular function andor congestive heart failure, age or 75 years, diabetes mellitus. 